JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M402753200 on June 14, 2004

J. Biol. Chem., Vol. 279, Issue 37, 38721-38729, September 10, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/37/38721    most recent
M402753200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Damdimopoulos, A. E.
Right arrow Articles by Spyrou, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damdimopoulos, A. E.
Right arrow Articles by Spyrou, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

An Alternative Splicing Variant of the Selenoprotein Thioredoxin Reductase Is a Modulator of Estrogen Signaling*

Anastasios E. Damdimopoulos, Antonio Miranda-Vizuete, Eckardt Treuter, Jan-Åke Gustafsson, and Giannis Spyrou{ddagger}

From the Department of Biosciences, Novum, Karolinska Institute, S-141 57 Huddinge, Sweden

Received for publication, March 11, 2004 , and in revised form, June 9, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The selenoprotein thioredoxin reductase (TrxR1) is an integral part of the thioredoxin system. It serves to transfer electrons from NADPH to thioredoxin leading to its reduction. Interestingly, recent work has indicated that thioredoxin reductase can regulate the activity of transcription factors such as p53, hypoxia-inducible factor, and AP-1. Here, we describe that an alternative splicing variant of thioredoxin reductase (TrxR1b) containing an LXXLL peptide motif, is implicated in direct binding to nuclear receptors. In vitro interaction studies revealed direct interaction of the TrxR1b with the estrogen receptors {alpha} and {beta}. Confocal microscopy analysis showed nuclear colocalization of the TrxR1b with both estrogen receptor {alpha} and {beta} in estradiol-17{beta}-treated cells. Transcriptional studies demonstrated that TrxR1b can affect estrogen-dependent gene activation differentially at classical estrogen response elements as compared with AP-1 response elements. Based on these results, we propose a model where thioredoxin reductase directly influences the estrogen receptor-coactivator complex assembly on non-classical estrogen response elements such as AP-1. In summary, our results suggest that TrxR1b is an important modulator of estrogen signaling.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Thioredoxin reductase (TrxR)1 is a selenocysteine containing enzyme (1) that catalyzes the reduction of thioredoxin (Trx) in the presence of NADPH constituting the so called thioredoxin system (2). In mammalian cells three TrxRs have been characterized, a cytoplasmatic one (TrxR1), a mitochondrial specific TrxR (TrxR2) (3), and more recently, a testis-specific one that can function both as a thioredoxin reductase and as glutathione reductase (4). TrxR1 purified from rat liver exists as a dimer of two identical 58-kDa subunits (5). In addition to reducing Trx, TrxR1 can reduce proteins such as protein-disulfide isomerase and plasma glutathione peroxidase (6). Furthermore, it has a wide range of low molecular weight targets such as dehydroascorbic acid, lipoic acid, selenite, and selenocysteine, it can cleave S-nitrosoglutathione (GSNO) to glutathione and nitric oxide (6) and can scavenge peroxynitrite (7). Recently, we also reported the reduction of ubiquinone by TrxR1 (8).

It has also been reported that TrxR1 is involved in the regulation of transcription factors such as p53, hypoxia-inducible factor and AP-1. Prostaglandins have been shown to covalently modify and inhibit the function of TrxR1 leading to the repression of p53 and hypoxia-inducible factor (9). Furthermore, TrxR1 is involved in promoting the cell death effect of combined interferon and retinoic acid (10, 11), caused by the TrxR1-dependent activation of p53-mediated gene expression (12, 13). In addition, p53-dependent gene expression was inhibited in yeast lacking TrxR because of the oxidation and inactivation of Trx, suggesting that the effect of TrxR1 on p53 activity is mediated by the reduction of Trx (14, 15). Recently, TrxR1 has also been shown to regulate the activation of AP-1 although this is also thought to occur through its function of reducing Trx1 (16). These examples indicate that TrxR1, alone and/or through Trx, may impact various transcriptional pathways.

Estrogen receptors (ERs) belong to the steroid/thyroid hormone receptor superfamily of nuclear receptors that upon binding of ligand are activated and bind to specific DNA response elements to initiate transcription of target genes (17). Apart from promoting DNA binding, the ligand-induced conformational change of the ligand binding domain of the receptors enables them to recruit coactivators such as GRIP1 and SRC-1 and the histone acetyltransferases p300/CBP and pCAF to the response elements, leading to activation of transcription (18, 19). In the case of ERs, it has been reported that, apart from the classical ER activation pathway that depends on the binding of ERs to the EREs (estrogen response elements), ER can regulate transcription even via AP-1 and SP-1 sites without ER binding to DNA (20-24).

We describe here a TrxR1 variant, referred to in this paper as TrxR1b, with an extension at the N terminus. Within the extra amino acid sequence we found the presence of a nuclear receptor motif (NR box) with the consensus sequence LXXLL, which mediates the binding of co-activators to their nuclear receptors (25). Indeed, the presence of an LXXLL motif in the TrxR1b leads to the direct interaction of the protein with ER{alpha} and ER{beta}. As a result of the TrxR1b binding to the ERs, the reductase is translocated into the nucleus and colocalizes with the ERs. Furthermore, whereas TrxR1b enhances the transcriptional activity of the ERs at the classical EREs it effectively represses ER activity at AP-1 sites, suggesting that TrxR1 could be an important regulator of ER activity and ER-dependent cellular growth and differentiation.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Plasmids—For the construction of the glutathione S-transferase (GST)-TrxR1b42-56 fusion, which includes the LXXLL motif found in the long form TrxR1, the oligos KDRF3' (5'-AATTCTTAAGGGCCGTTCATTTTTAGTAGCTTTTGAAGTCTGCCCTCCTGATAG-3') and KDRF5' (5'-GATCCTATCAGGAGGGCAGACTTCAAAAGCTACTAAAAATGAACGGCCCTTAAG-3') were annealed and subsequently ligated into an EcoRI- and BamHI-digested pGEX-4T3 vector. For the construction of the full-length protein-GST fusions, TrxR1a was amplified employing standard PCR techniques and the primers hTrxR15' NdeI (5'-CGACTGCATATGAACGGCCCTGAAGATCTTCCC-3') and hTrxR-13' BamHI (5'-CCATGCGGATCCGCAGCAGCCAGCCTGGAGGATGC-3'), whereas TrxR1b was amplified with the primers KDRF5' NdeI (5'-CGACTGCATATGTCATGTGAGGACGGTCGG-3') and hTrxR13' BamHI. The PCR products were purified and digested with NdeI and BamHI and then ligated into the pET11c vector. The open reading frame for GST was amplified from the pGEX-4T3 vector with the GST5' BamHI (5'-CAAGCTGGATCCATGTCCCCTATACTAGGTTATTGGAAAATTAAG-3') and GST3' BamHI (5'-CTAGCAGGATCCCTATTTTGGAGGATGGTCGCCACCACC-3') primers. After purification the PCR products were digested with BamHI and ligated in-frame into the pET11c vectors containing either TrxR1a or TrxR1b, resulting in a fusion where the GST protein is located at the C terminus of the reductases so that it should not interfere with the LXXLL motif located at the N terminus of the TrxR1. For the construction of GFP fusions the open reading frames of TrxR1a and TrxR1b were amplified with the hTR1 GFP-F1 (5'-GCGGGAGAATTCGCCACCATGGACGGCCCTGAAGATCTTCCCAAG-3'), hTR1 GFP-R1 (5'-GGATGGGGATCCACCGCAGCAGCCAGCC-3') and KDRF-GFP-F1 (5'-GCGGGAGAATTCGCCACCATGGCATGTGAGGACGGTC-3'), hTR1 GFP-R1 primer pairs, respectively, and cloned into the pEGFP-N3 vector at the EcoRI and BamHI sites. To generate red fluorescent fusion proteins we amplified the open reading frame of HcRed1 with the HcRed5'-BamHI-N3 (5'-AGTTAGGGATCCATGGTGAGCGGCCTGCTGAAGG-3') and HcRed3'-NotI (5'-CTTGAGCGGCCGCTCAGTTGGCCTTCTCGGGCAGGTC-3') primers from the pHcRed1-N1 vector and replaced the green fluorescent protein in the pEGFP-N3 by digestion with BamHI and NotI. Other plasmids used are described elsewhere: pIRESneo-TrxR1 (8), pSG5-ER{alpha} and pSG5-ER{beta} (26), 3xERE-TATA-luc (27), and Coll73-luc (20).

Antibody Generation and Western Blotting—Antibodies were generated by the injection of purified TrxR1a or synthesized peptide (KQRKIGGHGPTLKAY) into rabbits. The injection and bleedings were performed by AgriSera, Sweden. Immunoglobulins were precipitated from final bleeding serum by ammonium sulfate. In short, immune serum was diluted 1:1 (5 ml of serum + 5 ml of PBS). For this 10 ml, 2.26 g of ammonium sulfate was added under stirring to precipitate the immunoglobulins. After the addition of ammonium sulfate the sample was further incubated for 2 h on ice with slight stirring. The serum was centrifuged for 30 min at 4 °C at 35,000 x g. The pellet was resuspended in 5 ml of PBS and dialyzed extensively against PBS. Antibodies were then subjected to affinity purification against TrxR1a or the synthesized peptide using CNBr-activated Sepharose 4B and following the manufacturer's instructions (Amersham Biosciences).

The purified antibodies were used for Western blotting. Cell extracts prepared by sonication were subjected to SDS-PAGE and transferred to Hybond-P membrane (Amersham Biosciences) by standard techniques. The membrane was blocked for 1 h at room temperature in PBS-T (PBS + 0.1% Tween 20) complemented with 10% milk powder. The membrane was incubated with the antibody for 1 h at room temperature in PBS-T with 2% milk powder and subsequently washed 3x 10 min in PBS-T. The antibody was detected using horseradish peroxidase-linked anti-rabbit antibody and the ECL plus detection kit (Amersham Biosciences).

GST Pull-down Assays—The expression of the TrxR1/GST proteins was induced with 0.5 mM isopropyl-1-thio-{beta}-D-galactopyranoside at a cell density of A600 = 0.5 for 2 h. The fusion proteins were purified on glutathione-Sepharose beads according to standard protocols. Radiolabeled ER{alpha}/{beta}, glucocorticoid receptor (GR), and thyroid receptor {alpha} (TR{alpha}) were produced with the TNT T7 Coupled Reticulocyte Lysate System according the protocol from Promega. The in vitro translated proteins were incubated for 4 h at 4 °C with the TrxR1/GST proteins, bound to GST-Sepharose beads, in pull-down buffer (50 mM potassium Pi, 100 mM NaCl, 1 mM MgCl2, 10% glycerol, and 0.1% Tween 20) complemented with 1.5% bovine serum albumin. Ligands (E2, dexamethasone, and T3) were used at a concentration of 1 µM. After incubation, the beads were washed three times for 15 min in pull-down buffer and finally resuspended and boiled in SDS sample buffer. The proteins were separated in a 10% SDS-polyacrylamide gel and analyzed by autoradiography.

Transfections and GFP Analysis—HEK-293 cells were maintained in a 1:1 mixture of Dulbecco's modified Eagle's medium and F-12, supplemented with 10% fetal bovine serum and gentamycin. The transfection agent used was polyethylenimine (Sigma). 1 µg of DNA was diluted into a final volume of 10 µl of H2O, 0.5 µl of 0.1 M 25-kDa polyethylenimine was added and the sample was vortexed and incubated for 10 min at room temperature before it was added to the cells. For luciferase reporter transfections we used 500 ng of the reporter plasmid, 250 ng of pSG5-ER{alpha} or -{beta}, and 5 µg of the pIRESneo/TrxR1a or -b or pIRES/Trx1 and used polyethylenimine as the transfection agent. The amount of the DNA was kept constant by the addition of empty pIRESneo vector. For the GFP analysis, cells were transfected with 1 µg of the indicated DNA. After transfection, the cells were kept for 2 days in the presence of ligand, 25 nM E2 or 100 nM ICI 182, 780. Luciferase was measured using the luciferase assay kit from Biothema. The GFP analysis was performed with a Leica laser scanning confocal microscope. For the excitation of the GFP we used the 488-nm laser line and light was collected between 500 and 540 nm, whereas the excitation of HcRed was achieved with the 568-nm laser line and the emitted light was collected between 580 and 640 nm. Both live and fixed cells were used for the localization studies. For fixed cell studies, cells were seeded onto coverslips and transfected after 2 days. Cells were fixed in 3.7% paraformaldehyde for 30 min in room temperature and mounted using FluorSave Reagent (Calbiochem). For the fluorescence recovery after photobleaching (FRAP) studies cells were seeded onto tissue culture dishes for 2 days prior to transfection. Live cells were point bleached by exposing a limited area of the cell to a high intensity laser beam for 30 s using the 488-nm laser line and then images were acquired every 15-30 s.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of TrxR1a and -b—Several mRNA splicing variants exist for human TrxR1 (28). However, their translation results in only two different proteins. One of those, referred to as TrxR1b in this paper, contains an extra 52-amino acid sequence at the N terminus (Fig. 1, A and B). To study the specific expression of TrxR1b we raised an antibody (anti-TrxR1b) against amino acids 28-42 (KQRKIGGHGPTLKAY) within the extra amino acid sequence. The specificity of the anti-TrxR1b was demonstrated with Western blot analysis using extracts from HEK-293 cells transfected with expression plasmids for TrxR1a and -b and with fusions of the TrxRs with GFP. Two Western blots were performed in parallel, one developed with the specific anti-TrxR1b antibody and the other with an anti-TrxR1a antibody (Fig. 1C). An enhanced signal can be seen in the cells transfected with TrxR1b and TrxR1b-GFP, whereas cells transfected with TrxR1a and TrxR1a-GFP had the same signal as the untransfected cells when developed with the TrxR1b antibody. However, in the Western blot developed with the anti-TrxR1a we saw an increased signal in all the transfected cells further confirming the specificity of the anti-TrxR1b antibody as no TrxR1a is detected in the anti-TrxR1b blot (Fig. 1C, lanes TrxR1a and TrxR1a-GFP). The SDS analysis of in vitro translated TrxR1a and TrxR1b is shown in Fig. 1D.



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 1.
A, scheme showing the two different alternative splicing variants of TrxR1. The sequence shows the extra 52-amino acid sequence present in the N terminus of TrxR1b. Boxed is the NR box with the consensus sequence LXXLL. The peptide used for the production of the antibody is underlined. B, a scheme demonstrating the 5' exon arrangement of TRXR1 and the recombination that leads to the formation of an ATG in-frame with the ATG in exon 4. Splicing variants where exons 1 or 2 individually recombine with exon 4 leads to the translation being initiated by the ATG located in exon 4 and gives rise to the original TrxR1 (TrxR1a), whereas the formation of the ATG by the recombination of exons 1 and 2 leads to the extended TrxR1 variant (TrxR1b). C, Western blot detection of the TrxR1b and TrxR1a. Using a purified peptide antibody raised against amino acids 28-42 of TrxR1b or an anti-TrxR1a we were able to detect the endogenous expression of the protein in HEK-293 cells. The same cells were also transfected with plasmids expressing the two proteins, either as the wild-type or as a fusion with GFP, to confirm the specificity of the peptide antibody. D, in vitro translation of the two proteins.

 
To verify the expression of TrxR1b in human tissues we used extracts from different sources. As shown in Fig. 2A, TrxR1b is expressed in all tissues analyzed with particularly high expression in kidney, testis, uterus, ovary, and prostate. We also analyzed the expression of the protein in various cell lines (Fig. 2B). HeLa cells and HT cells express TrxR1b at high levels, whereas the level of expression in the other cell lines was lower. Furthermore, in tissues like testis and kidney as well as in cell lines such as HEK-293, HeLa, and HT, two bands are detected. The lower band seems to be a degradation product from TrxR1b. Even the cells transfected with a construct of TrxR1b give rise to two bands (Fig. 1C) suggesting that the lower band does not represent a product of alternative splicing. It has been demonstrated that the protein can be digested at amino acids 24 and 49 (29). This provides an explanation as to why we sometimes detect two bands. Because our antibody reacts to amino acids 28-42, the protein cleaved at amino acid 24 still contains the crucial amino acids for its detection; when cleaved at amino acid 49, however, the recognition sequence is discarded making the detection of the third expected band impossible.



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 2.
TrxR1b expression in tissues and cell lines. A, expression of TrxR1b in various human tissues as found by Western analysis using the protein medley system from Clontech and a peptide antibody raised against TrxR1b. B, Western analysis of various cell lines to confirm the expression of TrxR1b using the TrxR1b-specific antibody. C, expression of TrxR1a and -b in HEK-293 cells. Untransfected or TrxR1b- and TrxR1a-transfected HEK-293 cell extracts were analyzed by Western blotting using a polyclonal antibody against TrxR1a.

 
To compare the expression levels of TrxR1a and -b we used a polyclonal antibody raised against TrxR1a. Fig. 2C shows that the antibody can recognize both forms of the protein when cells were transfected with respective expression plasmids. However, in the untransfected and TrxR1a-transfected cells only one band is visible, corresponding to TrxR1a, whereas just a faint shadow is visible at the place one would expect TrxR1b, suggesting that TrxR1a is much more abundant in HEK-293 cells than TrxR1b. This is in accordance with previously reported results where a band of ~67 kDa copurifies with TrxR1a from human JPX9 cells, however, at significantly lower amounts. In conclusion, the TrxR1b appears to be widely expressed in both human tissues and cell lines and, furthermore, to be specifically cleaved at the N terminus in several tissues and cell lines.

TrxR1b Binding to the Estrogen Receptors—The most distinct feature of the extra amino acid sequence in TrxR1b is the presence of an NR box at amino acids 47-51 with the consensus sequence LXXLL (Fig. 1A). The LXXLL motif is present in the majority of nuclear receptor coregulators and is responsible for their binding to their respective nuclear receptor (25). The presence of an NR box in TrxR1b raises the question of whether the protein is able to bind to nuclear receptors. A fusion of GST with a peptide comprising amino acids 42-56 of TrxR1b (GSTTrxR1b42-56), including the NR box, was constructed to be used as bait to isolate interacting nuclear receptors. Subsequent GST pull-down experiments showed that both ERs could interact with GST-TrxR1b42-56. Furthermore, this interaction was estrogen dependent (Fig. 3A).



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 3.
TrxR1b but not TrxR1a binds to ER{alpha}/{beta} A, the NR box containing the peptide, amino acids 42 to 56, of TrxR1b was expressed as a fusion with GST and used in pull-down studies. ER{alpha} and -{beta} were in vitro translated and radiolabeled with [35S]methionine and incubated with the GST fusion proteins bound onto GST-Sepharose beads in the presence or absence of 1 µM E2. The sequence shows the peptide that was fused to the GST and used for the pull downs. Underlined is the NR box. B, pull-down assay with in vitro translated ER{alpha} or -{beta} and full-length TrxR1a or -b GST fusions in the presence or absence of 1 µM E2.

 
Fusions of the entire TrxR1a/b proteins with GST were used to confirm these results. As shown in Fig. 3B, TrxR1b was able to bind both ERs, and the binding was ligand dependent as previously shown for GST-TrxR1b42-56. TrxR1a did not show any binding, confirming that the interaction seen with TrxR1b is dependent on the N-terminal amino acid extension of TrxR1b. Taken together with the fact that the LXXLL peptide from TrxR1b fused to the GST was able to pull-down the ERs, strong evidence is thus provided that the binding is because of the LXXLL motif of TrxR1b. To further confirm the specificity of the binding to the LXXLL motif of TrxR1b a competition pull-down was performed (Fig. 4A). ER{alpha} and -{beta} were effectively competed away from the GST-TrxR1b by increasing concentrations of a peptide containing the second NR box of TIF2, which has a strong affinity for the ERs (30). We next examined the specificity of the interaction with ER{alpha}/{beta} versus other nuclear receptors. As shown in Fig. 4B, ER{alpha} has the strongest binding, with a higher pull-down yield than any other receptors shown. Indeed, GR did not show any binding while TR{alpha} interacts, although not with the same strength as observed with ER{alpha}. As demonstrated (Fig. 4B), TrxR1b pulls down more than 20% of the ER{alpha} input while ~5% of TR{alpha} is bound to the TrxR1b-GST. Taken together, these results indicate that the ERs are strong binding partners for TrxR1b and that the binding is dependent on the presence of the LXXLL motif at the N terminus.



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 4.
The interaction of TrxR1b to the ERs is dependent on its LXXLL motif. A, competitive pull-down assay. The specificity of the binding was investigated using full-length TrxR1b against a peptide containing the second NR box of TIF-2, shown in the sequence below the gel image. A series of dilutions in the 1:10 scale of the peptide were used during the incubation of TrxR1b-GST fusion with the in vitro translated ER{alpha}/{beta}. B, pull-down assay with various receptors. ER{alpha}, GR, and TR{alpha} were in vitro translated and used in pull-down assays together with the full-length TrxR1b-GST fusion to study the specificity of the interaction of TrxR1b toward ER. The ligands used were E2 for the ER{alpha}, dexamethasone for the GR, and T3 for TR{alpha}.

 
Nuclear Colocalization of TrxR1b with ER{alpha}/{beta} and Their Sub-nuclear Trafficking—ER{alpha}/{beta} and TrxR1a/b reside in different compartments of the cell. ER{alpha}/{beta} are localized mainly in the nucleus, whereas TrxR1a/b are mainly cytoplasmic (Fig. 5A) when these proteins are expressed in cells as fusions with GFP and HcRed, respectively. However, we show that, although TrxR1 is mainly a cytoplasmic protein, there are always low amounts of the protein present in the nucleus and ~5% of the cells have quite substantial amounts, with ~10% of the total amount of TrxR1a/b protein present in the nucleus (Fig. 5A). When cotransfecting GFP-ER{alpha}/{beta} with TrxR1b-HcRed, in the presence of E2, the localization pattern of TrxR1b in the nucleus changes, from mainly a homogeneous distribution to distinct spots colocalizing with ER{alpha}/{beta} (Fig. 5B). Furthermore, we observed that in the presence of ER and E2, the nuclear localization of TrxR1b would become more pronounced so ~35% of the cells would have more than 10% of the protein in the nucleus and furthermore, in ~10% of the cells, it was exclusively in the nucleus; this was not observed without cotransfection. TrxR1a, however, shows the same pattern as when transfected alone (Fig. 5C), i.e. it is mainly cytoplasmic with the nuclear portion of the protein homogeneously distributed in the nucleus with no apparent colocalization with ER{alpha}/{beta}.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 5.
ER{alpha}/{beta} both colocalize with TrxR1b. A, cells were transfected with either GFP-ER{alpha}/{beta} or TrxR1a/b-HcRed1 expression plasmids in the presence of E2. After 2 days cells were fixed and analyzed with a Leica confocal laser scanning microscope. B, cells were cotransfected with GFP-ER{alpha}/{beta} and TrxR1b-HcRed1 and kept for 2 days in media containing 25 nM E2 or 100 nM ICI. After the incubation period cells were fixed and analyzed. C, cells were cotransfected with GFP-ER{alpha} with TrxR1a-HcRed1 and kept for 2 days in media containing 25 nM E2.

 
The pull-down experiments revealed that the interaction between TrxR1b and ERs was estrogen dependent, therefore we investigated whether estrogen is important for colocalization of the proteins. For that reason we used the antiestrogen ICI and performed similar transfection experiments as described above. Fig. 5B shows that ICI effectively abolished nuclear colocalization of the ERs and TrxR1b. TrxR1b was no longer restricted to areas of the nucleus where ER was localized but was distributed throughout the entire nucleus. This suggests that the interaction of the ERs and TrxR1b is essential for their colocalization observed in the presence of E2.

To obtain quantitative data from the localization studies we analyzed the images and produced graphs of the fluorescent intensity over a certain area of the image, a fluorescence profile. The analysis was performed on the cells shown in Fig. 5B in the presence of either E2 or ICI. As shown in the graphs (Fig. 6) obtained from the cells in the presence of E2, the profile of TrxR1b and ER{alpha}/{beta} overlap, whereas in the presence of ICI the TrxR1b fluorescence assumes a more flat profile, no longer resembling the ER{alpha}/{beta} distribution, further demonstrating the importance of E2 for the colocalization pattern of the ERs and TrxR1b in the nucleus. However, this interaction does not seem to be necessary for the presence of TrxR1b in the nucleus, because part of the TrxR1b pool is in the nucleus even during ICI treatment (Fig. 5B) as well as in the absence of ERs (Fig. 5A). On the other hand, we were unable to find any cells where ERs and nuclear TrxR1b were not colocalized during E2 treatment. Furthermore, the fact that TrxR1b can be found almost exclusively in the nucleus of cotransfected cells suggests that the ER/TrxR1b interaction, although not essential for nuclear import of TrxR1b, might result in an accumulation of TrxR1b in the nucleus. Hence, both ER{alpha}/{beta} and E2 are required for TrxR1b to assume its structured/dotted nuclear pattern seen when colocalized with the ERs as the presence of only ER or E2 alone does not significantly change the cellular pattern of TrxR1b. Furthermore, the presence of the 52 extra amino acid sequence is required as the cellular localization of TrxR1a lacking those extra amino acids was not influenced by the presence of ERs and E2.



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 6.
Fluorescence profile of cotransfected ER{alpha}/{beta} and TrxR1b in the presence of either E2 or ICI. The area used for creating the profile is shown as a white line in the merged cell pictures.

 
Using the FRAP technique showed that ER{alpha} appears to be very mobile within the nucleus. Furthermore, this mobility is ligand-dependent but also dependent on proteasomes as the use of proteasome inhibitors causes the immobilization of ER (31). We performed FRAP experiments to further investigate interactions between TrxR1b and the ERs. Live cells cotransfected with ER{alpha} and TrxR1b were point bleached in the nucleus and images were captured every 15 s. In the presence of E2, ER{alpha} was colocalized with TrxR1b; after bleaching ER{alpha} recovers very fast, in a matter of seconds, and the same was true for TrxR1b (Fig. 7). Moreover, when point bleached for longer periods of time, the entire nucleus would become bleached, further confirming the pronounced mobility of both TrxR1 and ER{alpha}. Similar results were obtained with cotransfection of ER{beta}. This demonstrates that both ER and TrxR1b are mobile proteins and that the presence of TrxR1b does not seem to interfere with the dynamic intranuclear behavior of the ER.



View larger version (99K):
[in this window]
[in a new window]
  		FIG. 7.
Both ER and TrxR1b are mobile proteins in the nucleus as shown by the FRAP technique. GFP-ER{alpha} and TrxR1b-HcRed1 were cotransfected and the cells were kept for 2 days in E2 complemented media. Live cells were point bleached in the nucleus and images were subsequently acquired every 15 s. One representative experiment is shown. The white circles indicate the bleaching area.

 
Effect of TrxR on ER Transcriptional Activity—Because ER appears to relocate TrxR1b in the nucleus to areas where it resides itself we wondered whether TrxR1b could affect the transcriptional activity of ER. Cotransfections of ER{alpha}/{beta} with TrxR1a/b were performed and ER transcriptional activity was measured using a luciferase reporter vector under the regulation of an ERE-TATA. In the case of ER{alpha}, TrxR1b was capable of enhancing the transcriptional activity of the receptor 2-fold, whereas TrxR1a did not significantly affect ER{alpha} activity (Fig. 8A). In the case of ER{beta}, a 3-fold induction of its transcriptional activity was obtained in the presence of TrxR1b. However, in contrast to ER{alpha}, the ER{beta} activity was also enhanced by TrxR1a in a similar manner to TrxR1b (Fig. 8A). We then examined whether the ER{beta} activity could be enhanced by the cytosolic Trx as has been demonstrated for ER{alpha} (32). Indeed, as shown in Fig. 8B, Trx1 is a potent inducer of ER{beta} as it is for ER{alpha}, with a 4-fold induction of the ER transcriptional activity, suggesting that ER{beta} just like ER{alpha} can be redox regulated.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 8.
TrxR1 is able to enhance the ER transcription activity. A, TrxR1a and -b were transfected together with either ER{alpha} or -{beta} and an ERE-luciferase reporter plasmid was used to measure the transcriptional activity of the ERs. Cells were kept for 2 days in media complemented with E2 before lysis and luciferase analysis. B, cotransfection of either ER{alpha} or ER{beta} with Trx1 and the ERE-luciferase reporter plasmid in the presence of E2.

 
In addition to the classical ERE-dependent ER pathway, it has been shown that ER can affect transcription at AP-1 sites (20-22). Moreover, TrxR1a has been reported to regulate AP-1 activity (16). Could TrxR1a/b have any influence on the alternative pathway of ER transcriptional activity through AP-1? When the AP-1 reporter was transfected with either TrxR1a or -b, no differences could be observed between the two proteins. However, when either of the two ERs was added, a significant difference was found between TrxR1a and -b with respect to the AP-1 response (Fig. 9). Whereas in the presence of TrxR1a, both ERs were capable of inducing the AP-1 activity ~2-fold, but both ERs failed to induce the AP-1 in the presence of TrxR1b and instead a decreased AP-1 activity was observed. Thus, both TrxR1a and -b can act as an activator of ER{alpha} and -{beta} in the classical pathway by enhancing its transcriptional activity, most probably because of an increased reduced nuclear environment and through the reduction of Trx as is the case with several other transcription factors, whereas TrxR1b acts as a suppressor for both ERs in their alternative transcriptional pathways involving AP-1 sites. This effect can be explained by the physical protein-protein interaction shown in our proposed model (Fig 10), where TrxR1b could interfere with the assembly of AP-1 ER complex.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 9.
TrxR1b suppresses the ER-dependent AP-1 transcriptional activity. An AP-1 luciferase reporter plasmid was cotransfected with either TrxR1b or TrxR1a and with or without ER{alpha} or -{beta}. The cells were allowed to grow for 2 days after the transfection in the presence of E2 and were then lysed, followed by luciferase analysis.

 



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 10.
A, mode of action of the estrogen receptor on AP-1 response element as proposed by Kushner et al. (43). B, proposed model of the TrxR1b function on ER dependent AP-1 transactivation. DBD, DNA binding domain; CBP, CREB-binding protein; GRIP1, glucocorticoid receptor-interacting protein 1.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Studies on the genomic organization and mRNA expression of TRXR1 revealed that there are many splicing variants resulting from the 5' end of the TRXR1 gene (28). There are several exons present at the 5'-untranslated region of TRXR1, with the ATG for the original TrxR present in exon 4. When exons 1 and 2 together recombine with exon 4, a new ATG is formed that is in-frame with the start codon for the original TrxR1 and gives rise to a protein with a 52-amino acid extension with a theoretical molecular mass of ~60 kDa referred to here as TrxR1b. However, when TrxR1b was translated in vitro it migrated alongside the 66-kDa marker. To verify its existence in humans we produced a peptide antibody, specific for TrxR1b by targeting amino acids 28-42. The protein we detected in tissues and cell lines also had a molecular mass 66 kDa. Furthermore, in some tissues and cell lines we discovered a second protein migrating just below the 66-kDa band. This protein may be a degradation product of TrxR1b. Previously an oxidoreductase protein named KDRF was reported to be secreted by COS-1 cells when transfected with an expression plasmid for protein (29). However, instead of only one band, two more bands beneath the expected one were obtained and subsequent N-terminal sequencing revealed that those represented degradation products of KDRF; we have previously reported that KDRF is identical to TrxR1 apart from an extra N-terminal amino acid extension (33).

After confirmation of the expression of TrxR1b in several tissues and cell lines, we set out to determine the function of the extra N-terminal amino acid extension. Could this additional peptide provide a novel function to TrxR1? When analyzing the protein sequence we found the presence of an NR box; this box has the consensus sequence LXXLL and is responsible for the binding of coregulatory proteins to nuclear receptors (25). This suggested that TrxR1b might bind to nuclear receptors. Furthermore, it has been shown that peptides selected on the basis of a strong affinity to ER{alpha} often had an arginine before the first leucine in the LXXLL motif (34), just like the NR box in TrxR1b. In addition, peptides that can bind activated ER{alpha} have been divided into three subgroups according to their amino acids flanking the LXXLL motif (35). The TrxR1b motif did not fall into any of those classes, although it has a charged amino acid (Arg) upstream of the LXXLL motif, which is consistent with the class I peptides, it lacks the conserved serine found in the second position upstream of the NR box. TrxR1b bound to both ERs and apart from a weak binding to ER{beta} in the absence of ligand it did not display any preference for any of the ERs as demonstrated for TRAP220 (30) and the class II peptides that contain a proline as the second amino acids upstream the LXXLL motif (35).

To understand the biological significance of the in vitro interaction between ER{alpha}/{beta} and TrxR1b, the intracellular localization of these two proteins was investigated. In several studies it has been shown that the estrogen receptor is a nuclear protein (31, 36-38) and that ligand is important for the intranuclear distribution of the estrogen receptor (36, 38). In our experiments both ERs behaved in a similar manner giving rise to a structured nuclear pattern in HEK-293 cells in the presence of E2. On the other hand, TrxR1 has been considered to be a cytoplasmic protein, similar to our results, however, low levels of the proteins could be detected in the nucleus. Interestingly, histological studies on lung carcinoma biopsies have demonstrated strong immunoreactivity against TrxR1 in the nuclei of non-small lung cells (39). It is unclear how TrxR1 enters into the nucleus because neither TrxR1a nor Trx1Rb have any classical nuclear localization signals.

Cotransfection of fluorescent ERs and TrxR1a gave similar results as when these constructs were transfected individually. However, cotransfection of TrxR1b and ER changed the nuclear pattern of TrxR1b. TrxR1b relocates from a cytosolic or homogeneous nuclear distribution, and forms a dotted pattern colocalizing with both ERs. A similar nuclear redistribution has previously been reported for peroxisome proliferator-activated receptor {gamma} under the influence of RXR{alpha} (40). However, unlike TrxR1b, which is a cytosolic protein, peroxisome proliferator-activated receptor {gamma} is predominantly localized in the nucleus. A protein more relevant to TrxR1b would be the short form of metastatic tumor antigen 1 that similarly to TrxR1b is localized in the cytoplasm. It has been reported that metastatic tumor antigen 1 can bind ER but unlike TrxR1b the interaction of metastatic tumor antigen 1 and ER leads to the retention of the receptor in the cytoplasm (41). However, in our cotransfections, we could not detect any cytoplasmatic ER suggesting that TrxR1b is not able to retain ER into the cytoplasm and that ER is the dominant partner. When the experiments were performed in the presence of ICI, the localization pattern of TrxR1b once again changed. The presence of ER seems to be essential for the intranuclear distribution of TrxR1b but not for its nuclear localization, because cells that had only TrxR1b or TrxR1b and ER in the presence of ICI, still showed the presence of TrxR1b in the nucleus. Interestingly, when cotransfected with ER and TrxR1b, several cells showed TrxR1b exclusively in the nucleus, an observation that was never made when TrxR1b was transfected alone. Apparently, ER can bind to TrxR1b and change its subnuclear pattern but probably also inhibits its export from the nucleus leading to an accumulation of the protein in the nucleus.

ER{alpha} has been shown to be highly mobile within the nucleus in the absence of ligand (31). In the presence of E2 the mobility is reduced, which is thought to be caused by the binding of ER to the nuclear matrix, however, even though the mobility is reduced the protein is still dynamic. Similarly, it has been shown that GR is also highly mobile and undergoes rapid exchange with DNA-binding sites (42). The question was then if TrxR1b had the same dynamic intranuclear behavior as ER or if it could influence that of ER. To clarify this point we used the FRAP technique to study the intranuclear trafficking of the proteins. Both ERs and TrxR1b were found to be mobile. After bleaching, the recovery rate was similar for both proteins, indicating that the nuclear colocalization of ER and TrxR1b represents a dynamic process where both proteins retain their mobility. Furthermore, results obtained from transfections studying the transactivation function of the ERs in the presence of TrxR1b cannot be attributed to changes in the dynamics of the ERs because their mobility is intact.

Although ERs seem to have a drastic impact on the intranuclear localization of TrxR1b, one might ask whether TrxR1b has any effect on ER function. The activity of ER{alpha} has been found to be redox regulated with Trx as a mediator (32). Can TrxR1b directly affect ER or is Trx necessary to reduce ER and enhance transcription? In transient cotransfection experiments using an ERE TATA plasmid with luciferase as a reporter for ER activity, TrxR1b enhanced the transcriptional activity of ER. This might be explained by TrxR1b creating a reduced environment in the immediate vicinity of ER in the nucleus. In the case of ER{alpha}, only TrxR1b was active, whereas for ER{beta} both forms of TrxR1 acted as coactivators. In our system ER{beta} has an almost 7-fold lower activity than ER{alpha} on the ERE TATA reporter (data not shown); therefore even the low amounts of TrxR1a and Trx1 that could be present in the nucleus might influence ER{beta} activity through their reducing activity. In addition, TrxR1 has been shown to promote the nuclear localization of Trx1 (16), which is an activator of ER{alpha} (32). However, this has not yet been shown for ER{beta}, so we performed a cotransfection experiment to determine whether Trx1 is capable of enhancing ER{beta} activity. Indeed, Trx1 activated both ERs ~4-fold as compared with their basal activity. Because in our experiments ER{beta} has so much lower basal activity than ER{alpha}, even the presence of endogenous Trx1 could be sufficient to enhance the activity of ER{beta}, whereas for ER{alpha}, which is a very potent activator of the ERE TATA reporter, the endogenous Trx1 would affect the ER{alpha} activity only marginally.

We also examined the effect of TrxR1b on the alternative transcription pathway of ERs at AP-1 sites. In contrast to the classical pathway, TrxR1b appeared to diminish the activation of AP-1 by the ERs, whereas TrxR1a enhanced ER activity. It has been proposed that ER activates AP-1 by binding to coactivators that have already bound to the AP-1 and then triggers them to higher activity (43). We propose that TrxR1b could inhibit this activation by binding to ER and preventing it from binding to the AP-1 coactivator complex. In the presence of TrxR1b, the amount of ERs could thus be decreased at AP-1 sites and shifted toward ERE containing genes, thereby selectively enhancing the classical estrogen response pathway instead of the alternative AP-1 pathway.

The presence of an LXXLL motif in TrxR1b might also counteract its export from the nucleus and thus increase its concentration in the nucleus. It has been reported previously that Trx is translocated into the nucleus under conditions that induce oxidative stress such as during UV irradiation (44). We provide here a mechanism by which TrxR1b could accumulate in the nucleus to provide reducing equivalents to both Trx and nucleoredoxin, a nucleus-specific Trx-like protein that has been found to regulate transcription factors such as AP-1 and NF{kappa}B (45, 46). Thereby TrxR1b could indirectly regulate also redox-sensitive transcription factors other then ER, such as GR (47), NF-{kappa}B (48), AP-1 (49), SP1 (50), and p53 (51). However, the physical binding of TrxR1b to nuclear receptors suggests that TrxR1b might have a much more direct role in transcriptional regulation by interfering with the assembly of transcription complexes. TrxR1b could also be involved in chromatin regulation, as many proteins associated with ERs are proteins involved in chromatin remodeling and modification (52-55). Future studies are needed to clarify whether TrxR1b might be involved in the chromatin remodeling that occurs during ER activation of transcription.


   FOOTNOTES
 
* This work was supported by Swedish Medical Research Council Project Grants 13-X10370 and 19X-11622-03C, the Karolinska Institutet, Södertörns Högskola, and Swedish Medical Research Council Project Grants 038-14096-01A and 03X-14041-01A. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Dept. of Biochemistry, Institute of Biomedical Research of the Academy of Athens, Soranou Cfesiou 4, 11527 Athens, Greece. Tel.: 30-210-6597197; Fax: 30-210-6597545; E-mail: giannis.spyrou{at}cbt.ki.se.

1 The abbreviations used are: TrxR, thioredoxin reductase; AP-1, activator protein 1; E2, estradiol; ER, estrogen receptor; ERE, estrogen response element; FRAP, fluorescence recovery after photobleaching; GFP, green fluorescent protein; GR, glucocorticoid receptor; NR box, nuclear receptor box; Trx, thioredoxin; GST, glutathione S-transferase; PBS, phosphate-buffered saline; TR, thyroid receptor. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Gladyshev, V. N., Jeang, K. T., and Stadtman, T. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6146-6151[Abstract/Free Full Text]
  2. Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237-271[CrossRef][Medline] [Order article via Infotrieve]
  3. Miranda-Vizuete, A., Damdimopoulos, A. E., Pedrajas, J. R., Gustafsson, J. A., and Spyrou, G. (1999) Eur. J. Biochem. 261, 405-412[Medline] [Order article via Infotrieve]
  4. Sun, Q. A., Kirnarsky, L., Sherman, S., and Gladyshev, V. N. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3673-3678[Abstract/Free Full Text]
  5. Luthman, M., and Holmgren, A. (1982) Biochemistry 21, 6628-6633[CrossRef][Medline] [Order article via Infotrieve]
  6. Nordberg, J., and Arner, E. S. (2001) Free Radic. Biol. Med. 31, 1287-1312[CrossRef][Medline] [Order article via Infotrieve]
  7. Arteel, G. E., Briviba, K., and Sies, H. (1999) Chem. Res. Toxicol. 12, 264-269[CrossRef][Medline] [Order article via Infotrieve]
  8. Xia, L., Nordman, T., Olsson, J. M., Damdimopoulos, A., Bjorkhem-Bergman, L., Nalvarte, I., Eriksson, L. C., Arner, E. S., Spyrou, G., and Bjornstedt, M. (2003) J. Biol. Chem. 278, 2141-2146[Abstract/Free Full Text]
  9. Moos, P. J., Edes, K., Cassidy, P., Massuda, E., and Fitzpatrick, F. A. (2003) J. Biol. Chem. 278, 745-750[Abstract/Free Full Text]
  10. Hofmann, E. R., Boyanapalli, M., Lindner, D. J., Weihua, X., Hassel, B. A., Jagus, R., Gutierrez, P. L., Kalvakolanu, D. V., and Hofman, E. R. (1998) Mol. Cell. Biol. 18, 6493-6504[Abstract/Free Full Text]
  11. Ma, X., Karra, S., Guo, W., Lindner, D. J., Hu, J., Angell, J. E., Hofmann, E. R., Reddy, S. P., and Kalvakolanu, D. V. (2001) J. Biol. Chem. 276, 24843-24854[Abstract/Free Full Text]
  12. Hu, J., Ma, X., Lindner, D. J., Karra, S., Hofmann, E. R., Reddy, S. P., and Kalvakolanu, D. V. (2001) Oncogene 20, 4235-4248[CrossRef][Medline] [Order article via Infotrieve]
  13. Ma, X., Hu, J., Lindner, D. J., and Kalvakolanu, D. V. (2002) J. Biol. Chem. 277, 22460-22468[Abstract/Free Full Text]
  14. Pearson, G. D., and Merrill, G. F. (1998) J. Biol. Chem. 273, 5431-5434[Abstract/Free Full Text]
  15. Merwin, J. R., Mustacich, D. J., Muller, E. G., Pearson, G. D., and Merrill, G. F. (2002) Carcinogenesis 23, 1609-1615[Abstract/Free Full Text]
  16. Karimpour, S., Lou, J., Lin, L. L., Rene, L. M., Lagunas, L., Ma, X., Karra, S., Bradbury, C. M., Markovina, S., Goswami, P. C., Spitz, D. R., Hirota, K., Kalvakolanu, D. V., Yodoi, J., and Gius, D. (2002) Oncogene 21, 6317-6327[CrossRef][Medline] [Order article via Infotrieve]
  17. Steinmetz, A. C., Renaud, J. P., and Moras, D. (2001) Annu. Rev. Biophys. Biomol. Struct. 30, 329-359[CrossRef][Medline] [Order article via Infotrieve]
  18. Glass, C. K., and Rosenfeld, M. G. (2000) Genes Dev. 14, 121-141[Free Full Text]
  19. Bevan, C., and Parker, M. (1999) Exp. Cell Res. 253, 349-356[CrossRef][Medline] [Order article via Infotrieve]
  20. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. (1995) Mol. Endocrinol. 9, 443-456[Abstract]
  21. Webb, P., Nguyen, P., Valentine, C., Lopez, G. N., Kwok, G. R., McInerney, E., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J. A., Nilsson, S., and Kushner, P. J. (1999) Mol. Endocrinol. 13, 1672-1685[Abstract/Free Full Text]
  22. Bjornstrom, L., and Sjoberg, M. (2002) J. Biol. Chem. 277, 48479-48483[Abstract/Free Full Text]
  23. Safe, S. (2001) Vitam. Horm. 62, 231-252[Medline] [Order article via Infotrieve]
  24. Porter, W., Saville, B., Hoivik, D., and Safe, S. (1997) Mol. Endocrinol. 11, 1569-1580[Abstract/Free Full Text]
  25. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) Nature 387, 733-736[CrossRef][Medline] [Order article via Infotrieve]
  26. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. (1997) Science 277, 1508-1510[Abstract/Free Full Text]
  27. Kalkhoven, E., Valentine, J. E., Heery, D. M., and Parker, M. G. (1998) EMBO J. 17, 232-243[CrossRef][Medline] [Order article via Infotrieve]
  28. Osborne, S. A., and Tonissen, K. F. (2001) BMC Genomics 2, 10[Medline] [Order article via Infotrieve]
  29. Koishi, R., Kawashima, I., Yoshimura, C., Sugawara, M., and Serizawa, N. (1997) J. Biol. Chem. 272, 2570-2577[Abstract/Free Full Text]
  30. Warnmark, A., Almlof, T., Leers, J., Gustafsson, J. A., and Treuter, E. (2001) J. Biol. Chem. 276, 23397-23404[Abstract/Free Full Text]
  31. Stenoien, D. L., Patel, K., Mancini, M. G., Dutertre, M., Smith, C. L., O'Malley, B. W., and Mancini, M. A. (2001) Nat. Cell Biol. 3, 15-23[CrossRef][Medline] [Order article via Infotrieve]
  32. Hayashi, S., Hajiro-Nakanishi, K., Makino, Y., Eguchi, H., Yodoi, J., and Tanaka, H. (1997) Nucleic Acids Res. 25, 4035-4040[Abstract/Free Full Text]
  33. Miranda-Vizuete, A., and Spyrou, G. (1997) Biochem. J. 325, 287-288[Medline] [Order article via Infotrieve]
  34. Paige, L. A., Christensen, D. J., Gron, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C. Y., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., and Fowlkes, D. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3999-4004[Abstract/Free Full Text]
  35. Chang, C., Norris, J. D., Gron, H., Paige, L. A., Hamilton, P. T., Kenan, D. J., Fowlkes, D., and McDonnell, D. P. (1999) Mol. Cell. Biol. 19, 8226-8239[Abstract/Free Full Text]
  36. Stenoien, D. L., Mancini, M. G., Patel, K., Allegretto, E. A., Smith, C. L., and Mancini, M. A. (2000) Mol. Endocrinol. 14, 518-534[Abstract/Free Full Text]
  37. Saitoh, M., Takayanagi, R., Goto, K., Fukamizu, A., Tomura, A., Yanase, T., and Nawata, H. (2002) Mol. Endocrinol. 16, 694-706[Abstract/Free Full Text]
  38. Htun, H., Holth, L. T., Walker, D., Davie, J. R., and Hager, G. L. (1999) Mol. Biol. Cell 10, 471-486[Abstract/Free Full Text]
  39. Soini, Y., Kahlos, K., Napankangas, U., Kaarteenaho-Wiik, R., Saily, M., Koistinen, P., Paaakko, P., Holmgren, A., and Kinnula, V. L. (2001) Clin. Cancer Res. 7, 1750-1757[Abstract/Free Full Text]
  40. Akiyama, T. E., Baumann, C. T., Sakai, S., Hager, G. L., and Gonzalez, F. J. (2002) Mol. Endocrinol. 16, 707-721[Abstract/Free Full Text]
  41. Kumar, R., Wang, R. A., Mazumdar, A., Talukder, A. H., Mandal, M., Yang, Z., Bagheri-Yarmand, R., Sahin, A., Hortobagyi, G., Adam, L., Barnes, C. J., and Vadlamudi, R. K. (2002) Nature 418, 654-657[CrossRef][Medline] [Order article via Infotrieve]
  42. McNally, J. G., Muller, W. G., Walker, D., Wolford, R., and Hager, G. L. (2000) Science 287, 1262-1265[Abstract/Free Full Text]
  43. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. M., and Webb, P. (2000) J. Steroid Biochem. Mol. Biol. 74, 311-317[CrossRef][Medline] [Order article via Infotrieve]
  44. Hirota, K., Murata, M., Sachi, Y., Nakamura, H., Takeuchi, J., Mori, K., and Yodoi, J. (1999) J. Biol. Chem. 274, 27891-27897[Abstract/Free Full Text]
  45. Hirota, K., Matsui, M., Murata, M., Takashima, Y., Cheng, F. S., Itoh, T., Fukuda, K., and Yodoi, J. (2000) Biochem. Biophys. Res. Commun. 274, 177-182[CrossRef][Medline] [Order article via Infotrieve]
  46. Kurooka, H., Kato, K., Minoguchi, S., Takahashi, Y., Ikeda, J., Habu, S., Osawa, N., Buchberg, A. M., Moriwaki, K., Shisa, H., and Honjo, T. (1997) Genomics 39, 331-339[CrossRef][Medline] [Order article via Infotrieve]
  47. Makino, Y., Okamoto, K., Yoshikawa, N., Aoshima, M., Hirota, K., Yodoi, J., Umesono, K., Makino, I., and Tanaka, H. (1996) J. Clin. Investig. 98, 2469-2477[Medline] [Order article via Infotrieve]
  48. Hayashi, T., Ueno, Y., and Okamoto, T. (1993) J. Biol. Chem. 268, 11380-11388[Abstract/Free Full Text]
  49. Abate, C., Patel, L., Rauscher, F. J., 3rd, and Curran, T. (1990) Science 249, 1157-1161[Abstract/Free Full Text]
  50. Wu, X., Bishopric, N. H., Discher, D. J., Murphy, B. J., and Webster, K. A. (1996) Mol. Cell. Biol. 16, 1035-1046[Abstract]
  51. Hainaut, P., and Milner, J. (1993) Cancer Res. 53, 4469-4473[Abstract/Free Full Text]
  52. Kim, M. Y., Hsiao, S. J., and Kraus, W. L. (2001) EMBO J. 20, 6084-6094[CrossRef][Medline] [Order article via Infotrieve]
  53. Chen, D., Huang, S. M., and Stallcup, M. R. (2000) J. Biol. Chem. 275, 40810-40816[Abstract/Free Full Text]
  54. DiRenzo, J., Shang, Y., Phelan, M., Sif, S., Myers, M., Kingston, R., and Brown, M. (2000) Mol. Cell. Biol. 20, 7541-7549[Abstract/Free Full Text]
  55. Lamb, J., Ladha, M. H., McMahon, C., Sutherland, R. L., and Ewen, M. E. (2000) Mol. Cell. Biol. 20, 8667-8675[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles: